1.56

8.33% 0.12

Pre-market: 1.58 0.02 +1.28%

Proqr Therapeutics N V (PRQR)

Overview News Price History Option Chain Discussions Forecast

Proqr Therapeutics N V stock is traded at $1.56, with a volume of 719.40K. It is up +8.33% in the last 24 hours and down -1.89% over the past month. ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

Previous Close:

$1.44

Open:

$1.46

24h Volume:

719.40K

Relative Volume:

1.18

Market Cap:

$164.37M

Revenue:

$15.53M

Net Income/Loss:

$-52.71M

P/E Ratio:

-3.1045

EPS:

-0.5025

Net Cash Flow:

$-59.00M

1W Performance:

+1.96%

1M Performance:

-1.89%

6M Performance:

-36.33%

1Y Performance:

-17.02%

1-Day Range:

$1.4419

$1.585

1-Week Range:

$1.38

$1.585

52-Week Range:

$1.33

$3.10

Proqr Therapeutics N V Stock (PRQR) Company Profile

Name

Proqr Therapeutics N V

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

Address

Employee

187

Twitter

@proqr

Next Earnings Date

2026-08-06

Latest SEC Filings

PRQR's Discussions on Twitter

Compare PRQR vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRQR Proqr Therapeutics N V	1.56	164.37M	15.53M	-52.71M	-59.00M	-0.5025
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	Oppenheimer	Outperform
Apr-29-25	Resumed	Cantor Fitzgerald	Overweight
Apr-29-25	Initiated	Evercore ISI	Outperform
Mar-10-25	Upgrade	Citigroup	Neutral → Buy
Jan-10-25	Initiated	Oppenheimer	Outperform
Oct-29-24	Upgrade	Raymond James	Outperform → Strong Buy
Nov-08-23	Upgrade	Chardan Capital Markets	Neutral → Buy
Mar-30-23	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Dec-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-14-22	Downgrade	Citigroup	Buy → Neutral
Feb-11-22	Downgrade	Raymond James	Strong Buy → Mkt Perform
Feb-11-22	Downgrade	Stifel	Buy → Hold
Feb-01-22	Initiated	Raymond James	Strong Buy
May-03-21	Initiated	Stifel	Buy
Mar-25-21	Reiterated	Citigroup	Buy
Nov-03-20	Resumed	Cantor Fitzgerald	Overweight
Mar-12-19	Reiterated	Chardan Capital Markets	Buy
Dec-19-18	Initiated	RBC Capital Mkts	Outperform
Nov-15-18	Initiated	Citigroup	Buy
Sep-19-18	Initiated	Evercore ISI	Outperform
Sep-26-17	Reiterated	JMP Securities	Mkt Outperform
Jun-20-16	Initiated	Chardan Capital Markets	Neutral
Oct-15-14	Initiated	Deutsche Bank	Buy
Oct-13-14	Initiated	H.C. Wainwright	Buy

View All

Proqr Therapeutics N V Stock (PRQR) Latest News

Jun 14, 2026

ETFs Investing in ProQR Therapeutics N.V. Stocks - TradingView

Jun 14, 2026

Jun 08, 2026

ProQR Therapeutics (PRQR) Advances 3% as Biotech Sector Sentiment ImprovesPCR Extreme - newsline.com

Jun 08, 2026

Undervalued Penny Stocks To Consider In June 2026 - simplywall.st

Jun 08, 2026

Jun 03, 2026

Van Herk group (NASDAQ: PRQR) challenges ProQR 2026 AGM share capital proposals - Stock Titan

Jun 03, 2026